Drugs / Decitabine/cedazuridine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07814339 | Sep 2026 → Jun 2028 expected | acute myeloid leukemia | Rutgers, The State University of New Jersey | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine/cedazuridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07814339 ↗ |
| Route | Oral | “Oral decitabine/cedazuridine” NCT07814339 ↗ |